Metso Outotec Corp (0MGI)
London Exchange · UK · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 16.56 |
|---|---|
| 52-week range | 11.44 – 18.94 |
| Return, 1 month / 3 months | −3.5% / +10.7% |
| Return, 1 year / 3 years | +44.2% / +108.3% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 45 |
| Volatility (1 year) | 37.1% |
| Worst drawdown (1 year) | -21.1% |
| Average daily value traded | 5.05M EUR |
| Dividend yield | 2.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Metso Outotec is a Finnish industrial company that supplies equipment, parts and services for the mining, aggregates and metals refining industries. Its customers include mining companies, quarry operators and metal producers around the world. The company provides crushing and screening machinery, grinding mills, minerals processing systems and smelting and refining technology, along with maintenance and spare parts support. It is based in Helsinki, Finland, and serves customers across Europe, the Americas, Asia and Africa.
The shares are listed on the London Exchange in UK under the code 0MGI, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Metso Outotec Corp (0MGI) trades on the London Exchange in UK. It last closed at EUR 16.56 on 19 October 2026.
Its price-based Market X-Ray is 67 out of 100 (a fair price profile), ranking 766 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 44.2% and over the last three months it rose 10.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 64 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 3.1% | ||
| From 52-week high | -12.2% | ||
| Momentum | 75 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 10.7% | ||
| 6-month return | 5.4% | ||
| 12-month return, skipping the last month | 49.5% | ||
| Stability (higher is calmer) | 58 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 37.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -21.1% | ||
| Liquidity | 68 · Fair | Moderate trading activity. | |
| Average daily value traded | 5.05M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 74 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 2.4% | ||
| Years with dividends | 6 |
Strengths
- Momentum: Rising faster than most stocks on this exchange.
- Income: Dividend is high and has been paid regularly.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −2.9% |
|---|---|
| 1 month | −3.5% |
| 3 months | +10.7% |
| 6 months | +5.4% |
| 1 year | +44.2% |
| 3 years | +108.3% |
| 5 years | +128.0% |
Signals
| 50-day / 200-day average | 17.23 / 16.05 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.51 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 23 Apr 2026 | EUR 0.2000 |
| 23 Oct 2025 | EUR 0.1900 |
| 25 Apr 2025 | EUR 0.1900 |
| 24 Oct 2024 | EUR 0.1800 |
| 26 Apr 2024 | EUR 0.1800 |
| 27 Oct 2023 | EUR 0.1500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.